Current and investigational therapies used to alter the course of disease in multiple sclerosis
Current and investigational therapies used to alter the course of disease in multiple sclerosis
复制标题
DOI：
10.1097/00007611-199704000-00001
复制
发表时间：
1997-04-01
影响因子：
1.1
通讯作者：
Miller, A
中科院分区：
文献类型：
--
作者：
Miller, A
广泛的研究正在开发药物治疗药物，以防止与多发性硬化症（MS）相关的神经功能障碍的恶化和进展。最深入的研究策略涉及旨在通过减少炎症和改变免疫反应来限制脱髓鞘的药物。这一类包括干扰素β -lb，这是第一个被批准在临床试验之外使用的化合物；干扰素beta-1a;共聚物1。实验药物包括其他干扰素、甲氨蝶呤、亚胺胺、单克隆抗体、t细胞受体肽和2-氯脱氧腺苷。虽然皮质类固醇和促肾上腺皮质激素已被有效地用于治疗多发性硬化症的恶化，但它们作为疾病调节剂的作用目前还处于评估阶段。第二种策略，通过限制脱髓鞘和少突胶质细胞损伤来增强髓鞘再生，以蛋白质生长因子为代表。第三种治疗方法是改善脱髓鞘纤维的传导，以钾通道阻滞剂4-氨基吡啶和3,4-二氨基吡啶为代表。
Extensive research is under way to develop pharmacotherapeutic agents that will prevent the exacerbations and the progression of neurologic disability associated with multiple sclerosis (MS). The most intensive research strategy has involved agents intended to Limit demyelination by reducing inflammation and modifying the immune response. In this category are interferon beta-lb, the first compound approved for use outside of clinical trials; interferon beta-1a; and copolymer 1. Experimental agents include other interferons, methotrexate, linomide, monoclonal antibodies, T-cell receptor peptides, and 2-chlorodeoxyadenosine. Although they have been used effectively to treat exacerbations of MS, corticosteroids and corticotropin are now under evaluation as disease-modifying agents. A second strategy, enhancing remyelination by limiting demyelination and oligodendrocyte injury, is represented by protein growth factors. A third therapeutic approach, improving conduction in demyelinated fibers, is represented by the potassium channel blockers 4-aminopyridine and 3,4-diaminopyridine.